SCHEMBL25844139

SCHEMBL25844139

COc1cc(-c2cn(C)c(=O)c(C)c2C)ccc1C(=O)N1CCC(C(C)C)CC12CC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD9 Q9H8M2 9/20 0.39
BRD4 O60885 9/20 0.39
BRD2 P25440 2/20 0.39
BRD7 Q9NPI1 2/20 0.39
CYP3A4 P08684 1/20 0.36
TAF1 P21675 1/20 0.34
CECR2 Q9BXF3 1/20 0.34
KDM4E B2RXH2 2/20 0.34
MAPK1 P28482 2/20 0.34
ALDH1A1 P00352 1/20 0.34
TP53 P04637 1/20 0.34
KMT2A Q03164 1/20 0.34
HSD17B10 Q99714 1/20 0.34
ABL1 P00519 1/20 0.34
RIN1 Q13671 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
OXTR P30559 3/20 0.33
USP2 O75604 1/20 0.32
LMNA P02545 1/20 0.32
DPP4 P27487 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23798067 0.91 CACNA1B (0.35) BRD9BRD4BRD2BRD7CYP3A4
SCHEMBL25844132 0.85 BRD9 (0.45) BRD9BRD4BRD2BRD7CYP3A4
SCHEMBL25091099 0.79 CACNA1B (0.35) BRD9BRD4BRD2BRD7CYP3A4
SCHEMBL25091781 0.76 CACNA1B (0.45) BRD9BRD4BRD2BRD7CYP3A4
SCHEMBL25091100 0.71 BRD4 (0.46) BRD9BRD4BRD2BRD7CYP3A4
SCHEMBL25844193 0.69 BRD4 (0.44) BRD9BRD4TAF1CECR2KDM4E
SCHEMBL23798990 0.68 BRD9 (0.44) BRD9BRD4BRD2BRD7CYP3A4
SCHEMBL23134700 0.67 BRD4 (0.60) BRD9BRD4BRD2BRD7
SCHEMBL23798071 0.67 BRD9 (0.53) BRD9BRD4BRD2BRD7CYP3A4
SCHEMBL25844123 0.66 BRD9 (0.52) BRD9BRD4BRD2BRD7CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691972-B2 Compounds for targeted degradation of BRD9 C4 THERAPEUTICS, INC. (US) 2023-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691972-B2 Compounds for targeted degradation of BRD9 BRD9, BRD1, BRWD1 BRD9 1/4885BRD4 17/4885BRD2 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.